Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

January 17th 2024

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

January 16th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.

Sacibertinib Plus Endocrine Therapy Shows Early Safety, Activity in ER+/HER2+ Breast Cancer

January 16th 2024

Sacibertinib plus endocrine therapy had acceptable safety with early clinical activity in patients with ER+/HER2+ metastatic breast cancer.

Overcoming Challenges in Biomarker Testing in Breast Cancer

January 16th 2024

Experts on breast cancer discuss challenges encountered in biomarker testing for patients with breast cancer.

Testing for ESR1 Mutations in Breast Cancer

January 16th 2024

Kevin Kalinsky, MD, MS, and Erica L. Mayer, MD, MPH, discuss testing practices for ESR1 mutations in patients with breast cancer.

Sequential Neoadjuvant HER2 Blockade Plus Polychemotherapy Elicits Antitumor Activity in HER2+ Breast Cancer

January 13th 2024

Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, concomitant with trastuzumab/pertuzumab elicited responses in patients with HER2+ breast cancer.

Dr Hafez on Key Considerations For Treatment Selection in Early-Stage HER2+ Breast Cancer

January 12th 2024

Maria Hafez, MD, explains how hormone receptor status, risk stratification, & other factors influence clinical decisions in early HER2+ breast cancer.

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024

Drs Monk and Tarantino highlight current research investigating B7-H4–directed antibody-drug conjugates. in multiple solid tumor types.

SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 10th 2024

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

Dr Novik on Emergent Treatment Options in ER+ Breast Cancer

January 8th 2024

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.

Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification

January 7th 2024

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

January 5th 2024

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

Advani Spotlights Clinical Trial Implications Across Breast Cancer Subtypes

January 4th 2024

Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.

FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

January 4th 2024

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Dr Sammons on Treating Patients With Breast Cancer Who Present With Brain Metastases

January 3rd 2024

Sarah Sammons, MD, discusses the goals of treating patients with breast cancer who present with active vs stable brain metastasis.

Revisit the Top 5 OncLive On Air Episodes of 2023

December 29th 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

The Intersections of Career Direction and Personal Connections

December 27th 2023

With perseverance, compassion, and energy, Ann H. Partridge, MD, MPH, has devoted her career to shrinking the gaps in research and care for young women with breast cancer and improving their outcomes and quality of life along the way.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Capivasertib/Fulvestrant Approval Expands Options in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

December 22nd 2023

Sara M. Tolaney, MD, MPH, discusses the significance of the FDA approval of capivasertib and fulvestrant in this patient population, highlights the efficacy and notable toxicities seen in the CAPItello-291 trial, and touches on key considerations when selecting between this and other standard regimens following CDK4/6 inhibitor progression.

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

December 22nd 2023

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.